Phase II Randomized Study of Figitumumab Plus Docetaxel and Docetaxel Alone With Crossover for Metastatic Castration-Resistant Prostate Cancer
Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-13-1869
Full Text
Open PDFAbstract
Available in full text
Date
February 17, 2014
Authors
Publisher
American Association for Cancer Research (AACR)